I had a look at the annual report today and try to foresee what may be the range of the net profit for next year. Thought that I may be able to look for some value here..
If we believe a lot of the industry's talks about generic drug deflation being in the high single digit. Let's say 10% deflation. This will essentially shaved off $42M of gross profit(straight off the bottom line everything else being equal) for MYX assuming same revenue sales in generics division . The other 2 divisions, i.e. MCS and Specialty Brands have combined $90M Gross Profit for FY17. For MYX to maintain same net profit as per FY17, these 2 divisions need to increase by 50%. Not only that, this year's NPAT included $33M gross profit from once-off items. So, to maintain FY17 NPAT, the other divisions need to almost double their profit (i.e. increase by 42+33 = $75M) to make up for the generic drug price deflation impact.
Not a good position to be in indeed for MYX..
- Forums
- ASX - By Stock
- Fundamentals Are Strong
I had a look at the annual report today and try to foresee what...
-
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.81 |
Change
0.140(3.00%) |
Mkt cap ! $407.5M |
Open | High | Low | Value | Volume |
$4.80 | $4.85 | $4.73 | $571.8K | 119.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 556 | $4.76 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.81 | 1694 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 556 | 4.760 |
1 | 556 | 4.750 |
1 | 556 | 4.740 |
1 | 556 | 4.730 |
1 | 1200 | 4.700 |
Price($) | Vol. | No. |
---|---|---|
4.810 | 1694 | 1 |
4.830 | 556 | 1 |
4.840 | 556 | 1 |
4.850 | 5556 | 2 |
4.860 | 556 | 1 |
Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |